210 reports of this reaction
4.8% of all ARSENIC TRIOXIDE reports
#2 most reported adverse reaction
DIFFERENTIATION SYNDROME is the #2 most commonly reported adverse reaction for ARSENIC TRIOXIDE, manufactured by Cephalon, LLC. There are 210 FDA adverse event reports linking ARSENIC TRIOXIDE to DIFFERENTIATION SYNDROME. This represents approximately 4.8% of all 4,344 adverse event reports for this drug.
Patients taking ARSENIC TRIOXIDE who experience differentiation syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIFFERENTIATION SYNDROME is moderately reported among ARSENIC TRIOXIDE users, representing a notable but not dominant share of adverse events.
In addition to differentiation syndrome, the following adverse reactions have been reported for ARSENIC TRIOXIDE:
DIFFERENTIATION SYNDROME has been reported as an adverse event in 210 FDA reports for ARSENIC TRIOXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIFFERENTIATION SYNDROME accounts for approximately 4.8% of all adverse event reports for ARSENIC TRIOXIDE, making it one of the most commonly reported side effect.
If you experience differentiation syndrome while taking ARSENIC TRIOXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.